Chloe James

Summary

Country: France

Publications

  1. ncbi A unique clonal JAK2 mutation leading to constitutive signalling causes polycythaemia vera
    Chloe James
    INSERM U362, Institut Gustave Roussy, Paris XI University, PR1, 39 rue Camille Desmoulins, 94805 Villejuif Cedex, France
    Nature 434:1144-8. 2005
  2. ncbi A JAK2 mutation in myeloproliferative disorders: pathogenesis and therapeutic and scientific prospects
    Chloe James
    INSERM U362, Institut Gustave Roussy, Paris XI University, PR1, 39 rue Camille Desmoulins, 94805 Villejuif Cedex, France
    Trends Mol Med 11:546-54. 2005
  3. ncbi The hematopoietic stem cell compartment of JAK2V617F-positive myeloproliferative disorders is a reflection of disease heterogeneity
    Chloe James
    INSERM, U876, Bordeaux, France
    Blood 112:2429-38. 2008
  4. ncbi Mutation in TET2 in myeloid cancers
    Francois Delhommeau
    INSERM U790, Institut Gustave Roussy, Villejuif, France
    N Engl J Med 360:2289-301. 2009
  5. ncbi The JAK2 617V>F mutation triggers erythropoietin hypersensitivity and terminal erythroid amplification in primary cells from patients with polycythemia vera
    Sabrina Dupont
    INSERM Unité 790, Universite Paris Sud, Institut Gustave Roussy, 39 rue Camille Desmoulins, 94805 Villejuif, France
    Blood 110:1013-21. 2007
  6. ncbi Constitutive activation of STAT5 and Bcl-xL overexpression can induce endogenous erythroid colony formation in human primary cells
    Loic Garcon
    Unité U 790 Institut National de la Santé et de la Recherche Médicale INSERM, Institut Gustave Roussy, Villejuif, France
    Blood 108:1551-4. 2006
  7. ncbi Evidence for MPL W515L/K mutations in hematopoietic stem cells in primitive myelofibrosis
    Ronan Chaligne
    Institut National de la Sante et de la Recherche Medicale INSERM, U790, Universite Paris XI, Institut Gustave Roussy, Villejuif, France
    Blood 110:3735-43. 2007
  8. ncbi [A unique clonal JAK2 mutation leading to constitutive signalling causes polycythaemia vera]
    Valerie Ugo
    INSERM U 362, PR1, Institut Gustave Roussy, Villejuif, France
    Med Sci (Paris) 21:669-70. 2005
  9. ncbi Down-regulation of the RUNX1-target gene NR4A3 contributes to hematopoiesis deregulation in familial platelet disorder/acute myelogenous leukemia
    Dominique Bluteau
    INSERM, U1009, Villejuif, France
    Blood 118:6310-20. 2011
  10. ncbi New insights into the pathogenesis of JAK2 V617F-positive myeloproliferative disorders and consequences for the management of patients
    Jean Luc Villeval
    INSERM, U790, Institut Gustave Roussy, IGR, Villejuif, France
    Semin Thromb Hemost 32:341-51. 2006

Collaborators

  • William Vainchenker
  • Valerie Ugo
  • Valerie Camara-Clayette
  • Hana Raslova
  • Josef Prchal
  • Isabelle Godin
  • Jean-Luc Villeval
  • Francois Xavier Mahon
  • R Berger
  • Yann Lecluse
  • Francois Delhommeau
  • Jean Pierre Le Couedic
  • Sabrina Dupont
  • Dominique Bluteau
  • Nicole Casadevall
  • Aline Massé
  • Ronan Chaligne
  • Frederic Larbret
  • Loic Garcon
  • Iléana Antony-Debré
  • Orianne Wagner-Ballon
  • Thomas Robert
  • Patrick Gonin
  • Veronique Cordette-Lagarde
  • Morgane Hilpert
  • Remi Favier
  • Najet Debili
  • Hugues Ripoche
  • Laure Gilles
  • Sabina Swierczek
  • Isabelle Plo
  • Olivier Kosmider
  • Philippe Dessen
  • Antonio Alberdi
  • Severine Trannoy
  • Franck Viguie
  • Catherine Lacombe
  • Veronique Della Valle
  • Serge P Romana
  • Christophe Marzac
  • François J Dreyfus
  • Fabienne Robert
  • Olivier A Bernard
  • Jean Soulier
  • Michaela Fontenay
  • Stephane Giraudier
  • Frederic Mazurier
  • Rodolphe Besancenot
  • Serge Koscielny
  • Irene Teyssandier
  • Karim Maloum
  • Patrick Saulnier
  • Fanny Fava
  • Carole Tonetti
  • Annelise Bennaceur-Griscelli
  • Catherine Lacout
  • Christine Rivat

Detail Information

Publications10

  1. ncbi A unique clonal JAK2 mutation leading to constitutive signalling causes polycythaemia vera
    Chloe James
    INSERM U362, Institut Gustave Roussy, Paris XI University, PR1, 39 rue Camille Desmoulins, 94805 Villejuif Cedex, France
    Nature 434:1144-8. 2005
    ..As this mutation is also found in other myeloproliferative disorders, this unique mutation will permit a new molecular classification of these disorders and novel therapeutical approaches...
  2. ncbi A JAK2 mutation in myeloproliferative disorders: pathogenesis and therapeutic and scientific prospects
    Chloe James
    INSERM U362, Institut Gustave Roussy, Paris XI University, PR1, 39 rue Camille Desmoulins, 94805 Villejuif Cedex, France
    Trends Mol Med 11:546-54. 2005
    ..Such a recurrent and unique mutation leading to a tyrosine kinase deregulation would make a suitable target for the development of specific therapies...
  3. ncbi The hematopoietic stem cell compartment of JAK2V617F-positive myeloproliferative disorders is a reflection of disease heterogeneity
    Chloe James
    INSERM, U876, Bordeaux, France
    Blood 112:2429-38. 2008
    ..These experiments provide new insights into the pathogenesis of JAK2V617F MPD and demonstrate that a JAK2 inhibitor needs to target the HSC compartment for optimal disease control in classical MPD...
  4. ncbi Mutation in TET2 in myeloid cancers
    Francois Delhommeau
    INSERM U790, Institut Gustave Roussy, Villejuif, France
    N Engl J Med 360:2289-301. 2009
    ..The myelodysplastic syndromes and myeloproliferative disorders are associated with deregulated production of myeloid cells. The mechanisms underlying these disorders are not well defined...
  5. ncbi The JAK2 617V>F mutation triggers erythropoietin hypersensitivity and terminal erythroid amplification in primary cells from patients with polycythemia vera
    Sabrina Dupont
    INSERM Unité 790, Universite Paris Sud, Institut Gustave Roussy, 39 rue Camille Desmoulins, 94805 Villejuif, France
    Blood 110:1013-21. 2007
    ....
  6. ncbi Constitutive activation of STAT5 and Bcl-xL overexpression can induce endogenous erythroid colony formation in human primary cells
    Loic Garcon
    Unité U 790 Institut National de la Santé et de la Recherche Médicale INSERM, Institut Gustave Roussy, Villejuif, France
    Blood 108:1551-4. 2006
    ....
  7. ncbi Evidence for MPL W515L/K mutations in hematopoietic stem cells in primitive myelofibrosis
    Ronan Chaligne
    Institut National de la Sante et de la Recherche Medicale INSERM, U790, Universite Paris XI, Institut Gustave Roussy, Villejuif, France
    Blood 110:3735-43. 2007
    ..In contrast, erythroid progenitors remained EPO dependent. These results demonstrate that in PMF, the MPL W515L or K mutation induces a spontaneous megakaryocyte (MK) differentiation and occurs in a multipotent HSCs...
  8. ncbi [A unique clonal JAK2 mutation leading to constitutive signalling causes polycythaemia vera]
    Valerie Ugo
    INSERM U 362, PR1, Institut Gustave Roussy, Villejuif, France
    Med Sci (Paris) 21:669-70. 2005
  9. ncbi Down-regulation of the RUNX1-target gene NR4A3 contributes to hematopoiesis deregulation in familial platelet disorder/acute myelogenous leukemia
    Dominique Bluteau
    INSERM, U1009, Villejuif, France
    Blood 118:6310-20. 2011
    ..We propose that the down-regulation of NR4A3 in RUNX1-mutated hematopoietic progenitors leads to an increase in the pool of cells susceptible to be hit by secondary leukemic genetic events...
  10. ncbi New insights into the pathogenesis of JAK2 V617F-positive myeloproliferative disorders and consequences for the management of patients
    Jean Luc Villeval
    INSERM, U790, Institut Gustave Roussy, IGR, Villejuif, France
    Semin Thromb Hemost 32:341-51. 2006
    ....